Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AS3MT | Q9HBK9 | 5/20 | 1.00 |
| ▸ | NSD2 | O96028 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 4/20 | 0.52 |
| ▸ | PFKFB2 | O60825 | 2/20 | 0.51 |
| ▸ | PFKFB1 | P16118 | 2/20 | 0.51 |
| ▸ | PFKFB3 | Q16875 | 2/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5858348 | 0.93 | AS3MT (0.87) | AS3MTNSD2MEN1NPC1RAB9A | |
| SCHEMBL5857180 | 0.90 | AS3MT (1.00) | AS3MTNSD2MEN1NPC1RAB9A | |
| SCHEMBL10096171 | 0.84 | AS3MT (0.72) | AS3MTNSD2MEN1NPC1RAB9A | |
| SCHEMBL5857242 | 0.83 | AS3MT (0.73) | AS3MTNSD2MEN1KMT2AMAOB | |
| SCHEMBL5857851 | 0.82 | AS3MT (0.71) | AS3MTNSD2MEN1NPC1RAB9A | |
| SCHEMBL5857169 | 0.80 | AS3MT (0.66) | AS3MTNSD2MEN1KMT2AMAOB | |
| SCHEMBL5857001 | 0.79 | AS3MT (0.74) | AS3MTNSD2MEN1NPC1RAB9A | |
| SCHEMBL5857002 | 0.79 | AS3MT (0.74) | AS3MTNSD2MEN1NPC1RAB9A | |
| SCHEMBL5857151 | 0.76 | AS3MT (0.65) | AS3MTNSD2MEN1KMT2APFKFB2 | |
| SCHEMBL5857177 | 0.76 | AS3MT (0.62) | AS3MTNSD2MEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030123-B2 | Indole derivatives with vascular damaging activity | ASTRAZENECA AB (SE) | 2006-04-18 | — | — | US | disclosed |
| US-20030216356-A1 | Indole derivatives with vascular damaging activity | ASTRAZENECA AB (SE) | 2003-11-20 | — | — | US | disclosed |
| CN-1431999-A | Indole derivatives with vascular damagine activity | ASTRAZENECA AB (SE) | 2003-07-23 | — | — | CN | disclosed |
| EP-1289952-A1 | INDOLE DERIVATIVES WITH VASCULAR DAMAGING ACTIVITY | AstraZeneca AB (SE) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001092224-A1 | INDOLE DERIVATIVES WITH VASCULAR DAMAGING ACTIVITY | ASTRAZENECA AB (SE) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216356-A1 | Indole derivatives with vascular damaging activity | IDO1, IDO2, VEGFA | AS3MT 2271/4885NSD2 969/4885MEN1 3191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.